Skip to main content

Branded

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar
    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • Rexall welcomes expansion of 13 vaccinations available through retail pharmacy in Ontario

    MISSISSAUGA, Ontario  — Rexall pharmacists in Ontario are now permitted to administer 13 more vaccinations that prevent shingles, hepatitis and cervical cancer, as well as several vaccines to people that are travelling overseas.

  • FDA approves Pfizer’s eczema treatment Eucrisa
    SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced its approval of Pfizer’s Eucrisa (crisaborole). The ointment is indicated to treat mild to moderate eczema in patients two years of age and older. 
     

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim
    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly rolls out insulin discount program
    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     

  • Report: London Drugs could be first to market with medical marijuana

  • Lilly, AstraZeneca to team on Alzheimer’s treatment development
    INDIANAPOLIS — Eli Lilly and Co. and AstraZeneca are teaming up to co-develop a potential disease-modifying treatment for Alzheimer’s disease, the companies announced Friday. 
     
    The focus of the initiative, which will see Lilly making an upfront payment of $30 million to AstraZeneca, is an antibody called MEDI1814, which can potentially slow the progression of the illness and is currently in Phase 1 trials. 
     

  • Report: AstraZeneca to shed 700 U.S. jobs
    WILMINGTON, Dela. — AstraZeneca is set to eliminate some 700 positions in the U.S. by the early months of 2017, according to reports. The company told USA Today the cuts would take effect Feb. 10, with its Fairfax, Delaware headquarters seeing about 120 of the expected cuts, with other impacted roles spanning those that are field-based in both sales and non-sales. 
     
X
This ad will auto-close in 10 seconds